JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $6
JP Morgan analyst John Stansel maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $5 to $6.
Read original at benzingaStocks · News reference
Evolent Health Raises FY2026 Sales Guidance from $2.400B-$2.600B to $2.600B-$2.700B vs $2.503B Est
Evolent Health (NYSE:EVH) raises FY2026 sales outlook from $2.400 billion-$2.600 billion to $2.600 billion-$2.700 billion vs $2.503 billion estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 11:06 AM
- Checked
- Aug 6, 2026, 11:06 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
TD Cowen Maintains Buy on Evolent Health, Raises Price Target to $6
TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $5 to $6.
Read original at benzingaTiger Global Management Increases Stake In Evolent Health Inc By 99% To 11,063,912 Shares
Read original at benzingaTruist Securities Maintains Hold on Evolent Health, Lowers Price Target to $6
Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Hold and lowers the price target from $7 to $6.
Read original at benzinga